Buonaguro L, Tornesello M L, Gallo R C, Marincola Franco M, Lewis G K, Buonaguro F M
Laboratory of Molecular Biology and Viral Oncogenesis & AIDS Reference Center, Istituto Nazionale Tumori Fond. G. Pascale, Via Mariano Semmola, 1, 80131 Naples, Italy.
J Virol. 2009 Jan;83(1):304-13. doi: 10.1128/JVI.01606-08. Epub 2008 Oct 22.
We have recently shown that human immunodeficiency virus type 1 (HIV-1) Pr55(gag) virus-like particles (HIV-VLPs), produced in a baculovirus expression system and presenting a gp120 molecule from a Ugandan HIV-1 isolate of clade A, induce maturation and activation of monocyte-derived dendritic cells (MDDCs) with a production of Th1- and Th2-specific cytokines. Furthermore, HIV-VLP-loaded MDDCs are able to induce a primary and secondary response in autologous human CD4(+) T cells in an ex vivo immunization assay. In the present study, we show that similar data can be obtained directly with fresh peripheral blood mononuclear cells (PBMCs), and the HIV-1 seropositivity status, with either low or high viremia, does not significantly impair the immune activation status and the responsiveness of circulating monocyte CD14(+) cell populations to an immunogenic stimulus. Some HIV-1-seropositive subjects, however, show a complete lack of maturation induced by HIV-VLPs in CD14(+) circulating cells, which does not consistently correlate with an advanced status of HIV-1 infection. The established Th2 polarization in both HIV-seropositive groups is efficiently boosted by HIV-VLP induction and does not switch into a Th1 pattern, strongly suggesting that specific Th1 adjuvants would be required for therapeutic effectiveness in HIV-1-infected subjects. These results indicate the possibility of screening PBMCs for donor susceptibility to an immunogen treatment, which would greatly simplify the identification of "responsive" vaccinees as well as the understanding of eventual failures in individuals enrolled in clinical trials.
我们最近发现,在杆状病毒表达系统中产生的、带有来自乌干达A组HIV-1分离株的gp120分子的1型人类免疫缺陷病毒(HIV-1)Pr55(gag)病毒样颗粒(HIV-VLPs),可诱导单核细胞衍生的树突状细胞(MDDCs)成熟和激活,并产生Th1和Th2特异性细胞因子。此外,负载HIV-VLP的MDDCs能够在体外免疫测定中诱导自体人类CD4(+) T细胞产生初次和二次应答。在本研究中,我们表明直接使用新鲜外周血单核细胞(PBMCs)也能获得类似数据,并且HIV-1血清阳性状态,无论病毒血症水平高低,均不会显著损害循环单核细胞CD14(+)细胞群体的免疫激活状态和对免疫原刺激的反应性。然而,一些HIV-1血清阳性受试者的循环CD14(+)细胞中完全缺乏HIV-VLPs诱导的成熟,这与HIV-1感染的晚期状态并无一致关联。HIV-VLP诱导可有效增强两个HIV血清阳性组中已确立的Th2极化,且不会转变为Th1模式,这强烈表明在HIV-1感染受试者中实现治疗效果需要特定的Th1佐剂。这些结果表明有可能筛选PBMCs以确定供体对免疫原治疗的易感性,这将大大简化“反应性”疫苗接种者的识别以及对参与临床试验个体最终失败原因的理解。